


10th-12th March 2026 | London, UK

www.tpd-europe.com

Register By Friday
28th November to
Save Up to £1,000



6th Annual

TPD & Induced Proximity Summit Europe

Your European Hub to Expedite Induced Proximity Therapeutics to Clinic

Progressing PROTACS, Molecular Glues & Emerging Proximity Therapeutics to the Clinic with Improved Safety & Drug Properties to Target Undruggables in Oncology & Beyond

Expert Speakers Include:



Georg Winter
Life Science Director
AITHYRA Institute
for Biomedical AI



Alessio Ciulli
Founder, Director & Professor, Chemical, Structural Biology & Centre for Targeted Protein Degradation
University of Dundee



Jamie Im
Director, Medicinal Chemistry
Foghorn Therapeutics



Christian Dillon
Chief Scientific Officer
PhoreMost



Laura Gasparini
Scientific Director & Tau Pathobiology Area Leader
Abbvie



Louise Modis,
Chief Scientific Officer
Amphista

Proud to Partner With:



+44 (0)20 3141 8700

@ info@hansonwade.com

www.tpd-europe.com

[Targeted Protein Degradation](#)



Welcome

Expert Speakers

Agenda

Partner With Us

Register Your Place

The Home of European Induced Proximity Innovation

6th Annual
TPD & Induced Proximity Summit
Europe
10-12th March 2026 | London, UK

As clinical updates from the US continue to shape global momentum, the European TPD and induced proximity landscape is evolving. This growth is driven by strategic collaborations, major acquisitions such as **Sanofi's £7.2B purchase of Blueprint Medicines**, **Merck's acquisition of SpringWorks Therapeutics**, and a rising interest in novel mechanisms and non-oncology indications. However, key challenges remain in rational design, oral bioavailability, PK/PD modelling, and translational efficacy, particularly as the European field shifts focus from oncology to inflammatory and neurodegenerative diseases.

The **6th TPD & Induced Proximity Summit Europe** returns as the region's only dedicated scientific forum advancing the translation of PROTACs, molecular glues, and emerging proximity modalities toward clinical application. With a focused single-track agenda, participants will gain a comprehensive view of the most innovative European research and development strategies, complemented by clinical insights from leading global programs to inform rational design, translational decision-making, and strategic collaborations.

Across three content rich days, engage with **80+ CXOs, Directors, and Senior Scientists** in **Discovery Biology, Medicinal Chemistry, and Translational Development** to advance proximity-based therapeutics from discovery to clinical success. Examine practical approaches to overcome challenges in **hit identification, oral bioavailability, PK/PD optimisation, and mechanistic validation**, while leveraging first-in-human data to accelerate your own development programs.

With expanded content on molecular glues, extracellular degraders, neurodegeneration, and non-degradative modalities, this is your unique chance to stay ahead in the evolving induced proximity landscape. Whether you're advancing early discovery or preparing clinical candidates, this summit offers the **expertise, connections, and strategic insight to help move your proximity drugs from bench to bedside**.

We look forward to welcoming you to London.

The European TPD & Induced Proximity Team

Key Benefits of Attending

What's On in 2026?



80+
Attendees



26+
Expert
Speakers



8+
Hours of
Networking



3
Interactive
Workshops



1
Scientific
Poster
Session



Utilise antibody-based degraders to unlock extracellular and membrane-bound targets with case studies from **Laigo Bio** & **Sanofi** exploring how their platforms expand E3 ligase use and tissue-specific targeting in ways small molecules cannot



Achieve therapeutic breakthroughs in neurodegeneration with degraders & stabilisers as **Autotac Bio**, **AbbVie**, & **Ambagon** showcase approaches restoring proteostasis in tau, α -synuclein, and LRRK2-driven diseases now advancing into clinical trials



Redefine molecular glue discovery with biology-first strategies through insights from **GSK**, **Amphista**, **PhoreMost**, & the **AITHYRA Institute** on expanding glueable targets using proteomics, ternary complex modelling, and mechanistic validation



Accelerate clinical translation with first-in-human data & PK/PD modelling featuring **Autotac Bio**, **Merck**, & **Foghorn Therapeutics** on optimising dosing, exposure, and formulation using computational modelling and machine learning



Expand the frontier of induced proximity beyond degradation with **Ambagon**, **BindBridge**, & **Protai Bio** designing stabilisers and AI-guided glues to redirect or enhance protein function across human health and agriculture

Welcome

Expert Speakers

Agenda

Partner With Us

Register Your Place

Innovation in Close Proximity: What's New for 2026?

8th Annual
TPD & Induced Proximity Summit
Europe
10-12th March 2026 | London, UK

Welcome

Sessions Guaranteed to Stick with You:



Charting the Evolution & Future of Targeted Protein Degradation: From Fundamental Mechanisms to Translational Impact

Alessio Ciulli

Founder, Director & Professor - Chemical, Structural Biology & Centre for Targeted Protein Degradation
University of Dundee



Exploring Mechanistic Insights & Emerging Strategies in Molecular Glue Degradation to Enhance Selectivity & Translational Potential

Georg Winter

Life Science Director
AITHYRA Institute for Biomedical AI

Navigating VC Funding and Structuring Strategic Collaborations to Bridge Discovery and Clinical Translation in the European TPD Biotech Ecosystem



Ian Churcher
Founder & Chief Executive Officer
Janus Drug Discovery Consulting



Luka Nićin
Venture Capitalist
Pace Ventures



Tiziana Rosetti
Principal
Sofinnova Partners



Mary Canning
Partner
Epidarex Capital



Damian Crowther
Entrepreneur in Residence
Cambridge Innovation Capital

Expert Speakers

3 Deep-Dive Workshops



Designing Antibody-Based Degraders to Overcome ADC Limitations & Unlock New Therapeutic Opportunities for TPD

With:



Expanding Degradation Applications Beyond Oncology to Unlock New Therapeutic Opportunities in Immunology, CNS & Rare Diseases

With:



Identifying Tractable Targets for Molecular Glues & Moving Beyond Cereblon Chemistry to Recruit Neo-Substrates Against More Indications

With:



Agenda

New Companies for 2026 Include:



Partner With Us

Showcase Your Scientific Poster



Contribute to the conversation and share your cutting-edge research with the induced proximity community to showcase your breakthrough discoveries to a vast audience of experts

Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

Register Your Place

Academic Pioneers



Alessio Ciulli
Founder, Director & Professor, Chemical, Structural Biology & Centre for Targeted Protein Degradation
University of Dundee



Georg Winter
Life Science Director
AITHYRA Institute for Biomedical AI



Radosław Nowak
Professor, Immune Engineering & Drug Discovery
The University of Bonn



Victor Guallar
ICREA Professor & Group Leader
Barcelona Supercomputing Center



Zoran Rankovic
Director & Professor, Chemical Biology & Protein Degradation
Center for Protein Degradation
Institute of Cancer Research

Pharma Powerhouses



Björn Niebel
Senior Principal Scientist
Sanofi Large Molecule Research



Carlos Martinez Fleites
Scientific Leader, Molecular Modalities
Discovery
GSK



Christin Rakers
Principal Scientist, Computational Chemistry
Merck



Christopher Woelk
External Innovation Partner (Oncology)
Astellas Pharma




Laura Gasparini
Scientific Director & Tau Pathobiology Area Leader
Abbvie

Investment Leaders



Damian Crowther
Entrepreneur in Residence
Cambridge Innovation Capital & SV Health Investors DDF



Luka Nićin
Venture Capitalist
Pace Ventures



Mary Canning
Partner
Epidarex Capital



Tiziana Rosetti
Principal
Sofinnova Partners

Your Expert Speakers

8th Annual
TPD & Induced Proximity Summit
Europe
10-12th March 2026 | London, UK

Welcome

Expert Speakers

Agenda

Partner With Us

Register Your Place

Biotech Visionaries



Changhoon Ji
Chief Technology Officer
Autotac Bio



Chris Tame
Founder & Chief Executive
Officer
Ternary Therapeutics



Christian Dillon
Chief Scientific Officer
PhoreMost



Christian Ottmann
Founder & Chief
Technology Officer
Ambagon Therapeutics



George Crane
Co-Founder & Chief
Executive Office
Bindbridge



Ian Churcher
Founder & Chief Executive
Officer
**Janus Drug Discovery
Consulting**



Jamie Im
Director, Medicinal
Chemistry
Foghorn Therapeutics



Kirill Pevzner
Chief Technology Officer &
Co-Founder
Protai Bio



Louise Modis
Chief Scientific Officer
Amphista



Martin Stahl
Chief Scientific Officer
Zenith Therapeutics



Maureen Galmes-Spit
Vice President Research
Laigo Bio



Simon Glerup
Chief Scientific Officer
Draupnir Bio



Shyra Gardai
Chief Scientific Officer
Epibiologics

“ An ideal space to connect, all at once,
to diverse people working in so many
complementary aspects in degradation ”

**Victor Guallar, ICREA Professor & Group
Leader, Barcelona Supercomputing Center**

Pre-Conference Workshop Day

Tuesday, 10th March

7.30 Check-In, Coffee & Networking

8.30 - 10.30

Workshop A

Designing Antibody-Based Degraders to Overcome ADC Limitations & Unlock New Therapeutic Opportunities for TPD

As antibody-derived degraders emerge as a powerful alternative to small molecules, this workshop will teach you how to engineer and optimise these biologics to unlock new extracellular degradation strategies.

We will cover:

- Comparing antibody-based degraders with PROTACs and molecular glues to highlight expanded E3 ligase use and tissue-specific targeting enabled by **Laigo's** platform
- Leveraging NANOBODY® VHH and antibody engineering to enable precise target engagement and novel extracellular degradation strategies
- Elucidating biodistribution and internalisation pathways to ensure targeted delivery of DACs and minimise off-target effects across tissues and cell types

This workshop is ideal for scientists exploring how antibody-derived scaffolds can extend targeted protein degradation beyond intracellular targets.

Workshop Leaders



Maureen Galmes-Spit
Vice President
Research
Laigo Bio



Björn Niebel
Senior Principal
Scientist
Sanofi Large Molecule Research

10.30 Morning Break & Networking

11.00 - 13.00

Workshop B

Harnessing Autophagy & Molecular Glue Strategies to Enable Degradable Therapeutics in Neurodegeneration & Complex Disease Areas

As degraders expand into non-oncology indications, this workshop will show you how autophagy-mediated and molecular glue approaches are being applied to tackle neurodegenerative diseases and other biologically complex conditions.

We will cover:

- Demonstrating the role of molecular glue-mediated stabilisation in restoring proteostasis in tau, α -synuclein, and LRRK2-driven neurodegeneration
- Showcasing the bimodal mechanism-of-action of the AUTOTAC platform in targeted protein degradation and selective autophagy activation, with a focus on translation of basic research findings for drug discovery
- Autophagy-mediated clearance of pathological protein aggregates in neuronal models of neurodegenerative diseases

This workshop is ideal for biologists and chemists exploring TPD approaches in non-oncology settings, from target selection to translation.

New Data

Workshop Leaders



Laura Gasparini
Scientific Director
& Tau Pathobiology
Area Leader
Abbvie



Christin Rakers
Principal Scientist
Computational
Chemistry
Merck



Changhoon Ji
Chief Technology
Officer
Autotac Bio

Pre-Conference Workshop Day

Tuesday, 10th March

13.00 Networking Lunch

14.00-16.00

Workshop C

Identifying Tractable Targets for Molecular Glues & Moving Beyond Cereblon Chemistry to Recruit Neo-Substrates Against More Indications

As molecular glue development moves beyond cereblon, this workshop will teach you how to identify tractable ligase-substrate pairs and validate glue activity to unlock new degradation strategies.

We will cover:

- Developing molecular glue discovery platforms to accelerate identification of novel degraders beyond cereblon
- Modelling and validating new ligases to enable degradation of intrinsically disordered proteins (IDPs)
- Applying genetic and phenotypic screening approaches to pinpoint ligases, map degrons, and confirm true glue activity
- Exploring alternative ligase recruitment strategies to overcome G-loop dependency and bind novel neo-substrates

This workshop is ideal for discovery biologists and medicinal chemists expanding molecular glue development beyond cereblon

New Data

Workshop Leaders



Martin Stahl
Chief Scientific Officer
Zenith Therapeutics



Victor Guallar
ICREA Professor & Group Leader
Barcelona Supercomputing Center



Zoran Rankovic
Director & Professor
- Chemical Biology & Protein Degradation
Center for Protein Degradation
Institute of Cancer Research

16.00 End of Pre-Conference Workshop Day

“ Exchanging ideas with other innovative companies in the TPD field at this summit will spark new collaborations and accelerate new developments ”

**Arnout Chepers, Chief Executive Officer,
TenAces Biosciences**

Conference Day One

Wednesday, 11th March

8th Annual
TPD & Induced Proximity Summit
10-12th March 2026 | London, UK



8.00 **Check-in, Coffee & Networking**

8.45 **Chair's Opening Remarks**

Redefining Targeted Protein Degradation to Transform Mechanistic Insight into Clinical Breakthroughs



Alessio Ciulli
Founder, Director & Professor, Chemical, Structural Biology & Centre for Targeted Protein Degradation
University of Dundee

New Data

9.00 **Charting the Evolution & Future of Targeted Protein Degradation: From Fundamental Mechanisms to Translational Impact**

- Reflecting on the evolution of the TPD field, from early degrader design principles to today's landscape of molecular glues and emerging proximity modalities
- Showcasing latest advances from the Ciulli Lab in mechanistic understanding and chemical biology of degraders, including unpublished data on previously undruggable targets and ternary complex formation
- Highlighting collaborative academic and industry consortia tackling grand challenges in paediatric cancers and neurodegenerative diseases
- Exploring the translational frontier, from spin-out innovation and pharma partnerships to future directions that will define the next generation of proximity-based therapeutics



Changhoon Ji
Chief Technology Officer
Autotac Bio

Clinical Update

9.45 **First-in-Human Evaluation of ATB2005A to Establish Clinical Proof of Concept for Autophagy-Based Degraders in Neurodegeneration**

- Delivering first-in-human clinical findings from the world's inaugural autophagy-targeting degrader for neurodegenerative disease
- Demonstrating safety, pharmacokinetics, and exposure outcomes from single- and multiple-ascending dose studies to validate clinical feasibility
- Advancing formulation and translational development of ATB2005A in canine dementia models to strengthen cross-species proof-of-concept and accelerate therapeutic advancement



10.15 **Morning Break & Speed Networking**

This networking session is your opportunity to get face-to-face with many of the brightest minds working in TPD and induced proximity to establish meaningful connections to pursue for the rest of the conference

Advancing Molecular Glue Discovery Through Target Expansion, Mechanistic Validation & Biology-First Approaches to Enable Precision Therapeutics Across Diverse Modalities



Georg Winter
Life Science Director
AITHYRA Institute for Biomedical AI

New Data

11.00 **Exploring Mechanistic Insights & Emerging Strategies in Molecular Glue Degradation to Enhance Selectivity & Translational Potential**

- Examining emerging mechanistic principles governing molecular glue-induced degradation and target selectivity
- Optimising experimental and assay-based strategies to elucidate degradation pathways and functional outcomes
- Exploring opportunities to expand molecular glue applications beyond traditional mechanisms



Carlos Martinez Fleites
Scientific Leader, Molecular Modalities Discovery
GSK

New Data

11.30 **Decoding Ternary Complex Formation to Advance Mechanistic Understanding in Molecular Glue Discovery**

- Elucidating the mechanistic drivers of ternary complex formation to improve predictability in molecular glue discovery
- Designing assays that detect and stabilise protein-protein interactions under the right biophysical conditions to enhance screening accuracy
- Applying mechanistic insights to build models that guide hit identification and inform future induced proximity modalities beyond molecular glues

Conference Day One

Wednesday, 11th March

12.00 Fireside Chat: Navigating Phenotypic Screening & Biology-First Strategies for Novel Induced Proximity Therapeutics

- Evaluating the strengths and limitations of phenotypic screening for discovering novel proximity therapeutics
- Comparing biology-first versus chemistry-first approaches to proximity drug discovery
- Leveraging biology-first strategies to unlock non-degrader modalities such as stabilisers, modulators and activators by anchoring discovery in disease-relevant phenotypes and mechanistic pathways
- Addressing the complexity of biological assay readouts in non-oncology indications and discussing how inflammation, neurodegeneration and other areas challenge traditional screening assays



Zoran Rankovic

Director & Professor, Chemical Biology & Protein Degradation Center for Protein Degradation
Institute of Cancer Research



Radosław Nowak

Professor, Immune Engineering & Drug Discovery
The University of Bonn



12.30 Networking Lunch

Expanding Ligase Biology & Structure-Guided Design to Build Versatile Discovery Platforms & Accelerate Translation of Novel Molecular Glue Therapeutics

13.30 Discovering & Validating Novel E3 Ligases to Expand Degradation Utility & Achieve Proof-of-Concept Across Diverse Targets



Christian Dillon
Chief Scientific Officer
PhoreMost

New Data

Noval Ligase

- Applying phenotypic and functional genomics screens to uncover novel E3 ligases with translational relevance
- Establishing mechanistic and *in vivo* validation to demonstrate degrader efficacy and tissue selectivity
- Exploring the potential for broad target applicability and therapeutic versatility of emerging ligase systems

14.00 Advancing Amphista's Targeted Glue™ Platform Through Structure-Guided Design & Rational Ligase Selection



Louise Modis
Chief Scientific Officer
Amphista

Noval Ligase

- Integrating structural biology, bioinformatics and chemoinformatics to rationally design Targeted Glues™ that achieve selective degradation across diverse targets
- Demonstrating mechanistic insights and preclinical progress of SMART T degraders employing distinct E3 ligases to validate platform versatility
- Applying structure-guided principles to accelerate translation of novel glue–ligase combinations from discovery to clinical readiness

14.30 Building a Computational Design Platform for Any Molecular Glue



Chris Tame
Founder & Chief Executive Officer
Ternary Therapeutics

- Discussing the requirements of a successful molecular glue design platform
- Blending the speed and scalability of machine learning with the accuracy of physics-based methods for optimal protein-protein matching and ternary complex structure prediction
- Computational design and experimental validation of optimised molecular glue degraders and activators



15.00 Afternoon Networking Break & Poster Session

Contribute to the conversation and showcase your groundbreaking research in TPD and induced proximity drug discovery and development. To present a poster, register your place and submit an abstract highlighting your latest discovery.

Harnessing AI, Structural Proteomics & Generative Design to Accelerate Hit Validation, Lead Optimisation & Expand Induced Proximity Modalities Beyond Therapeutics

15.45 Harnessing AI & Structural Proteomics to Drive Rational Design and Lead Optimisation in Molecular Glue & Degradation Discovery



Kirill Pevzner
Chief Technology Officer & Co-Founder
Protai Bio

- Demonstrating how the AIMS (AI + MS) platform integrates AI modelling and structural proteomics to map protein interactions and inform degrader design
- Showcasing lead optimisation strategies to enhance efficacy, selectivity, and rational design of molecular glues and degraders
- Presenting preclinical results from Protai's CAR-T6 degrader program as a case study of data-driven optimisation from discovery to *in vivo* validation

Conference Day One

Wednesday, 11th March



George Crane
Co-Founder & Chief
Executive Officer

Bindbridge

New Data

Noval Ligase

16.15 Leveraging Generative AI for the Discovery & Design of Molecular Glues for Agriculture

- Applying computational and AI-driven discovery workflows to design plant-specific degraders and glues with novel E3 ligases
- Translating human-targeted induced proximity principles into plant biology to expand modality reach beyond traditional therapeutics
- Exploring how agricultural molecular glues can inform next-generation discovery in human health through shared mechanistic insights

16.45 Chair's Closing Remarks

17.00 End of Conference Day One

“ This meeting brings together investors, innovators, and decision-makers across the TPD ecosystem. It's a rare opportunity to build relationships that can accelerate collaborations, funding, and strategic alliances ”

Tiziana Rosetti, Principal, Sofinnova Partners

Welcome

Expert Speakers

Agenda

Partner With Us

Register Your Place



Conference Day Two

Thursday, 12th March



8.30 Check-In, Coffee & Light Breakfast

9.15 Chair's Opening Remarks

Building Sustainable Value in the European TPD Biotech Ecosystem Through Venture Investment, Partnership Models & Translational Alignment

9.30 Panel Discussion: Navigating VC Funding & Structuring Strategic Collaborations to Bridge Discovery & Clinical Translation in the European TPD Biotech Ecosystem

- Understanding European VC expectations to enable biotechs to tailor fundraising strategies and secure investment in a competitive climate
- Identifying how recent deals signal which emerging modalities – like novel ligases, non-oncology therapeutics, and going beyond the proteosome – investors are looking for as priorities evolve in the TPD space
- Examining how early-stage proof-of-concept studies help validate platforms and increase commitment from pharma and VC partners
- Discussing how biotech–pharma–academia collaborations are structured in Europe to balance innovation, IP ownership, and translational potential

Moderator:



Ian Churcher
Founder & Chief Executive Officer
Janus Drug Discovery Consulting



Mary Canning
Partner
Epidarex Capital



Damian Crowther
Entrepreneur in Residence
Cambridge Innovation Capital & SV Health Investors DDF



Tiziana Rosetti
Principal
Sofinnova Partners



Luka Nićin
Venture Capitalist
Pace Ventures



Christopher Woelk
External Innovation Partner (Oncology)
Astellas Pharma



10.30 Morning Break & Networking

Engineering Bispecific & Extracellular Degradable Modalities to Overcome Delivery Barriers & Enable Tissue-Selective Targeting



Maureen Galmes-Spit
Vice President Research
Laigo Bio
New Data

11.00 Developing Bispecific Antibody Degradable Modalities to Achieve Tissue-Specific Degradation of Membrane Proteins

- Engineering bispecific antibody degraders to enable selective, lysosomal degradation of target membrane proteins
- Pairing therapeutic targets with membrane E3 ligases to achieve tissue-specific degradation while sparing healthy tissues
- Expanding therapeutic reach to hard-to-drug and challenging membrane targets



Simon Glerup
Chief Scientific Officer
Draupnir Bio

11.30 Developing Novel Extracellular Degradable Formats to Overcome Biodistribution & Internalisation Challenges in Complex Tissues

- Leveraging proteomics to identify compatible target–internalisation driver pairs that support tissue-specific degradation and therapeutic precision
- Exploring non-proteasomal degradation pathways to expand modality options and reduce toxicity associated with intracellular accumulation
- Integrating sweeping mechanisms to recycle biologics while degrading targets to improve durability and reduce off-target degradation



Conference Day Two

Thursday, 12th March

12.00 Presenting the Journey to the Clinic for a Novel Bispecific Antibody EpiTAC that Selectively Degrades EGFR in Tumours



Shyra Gardai
Chief Scientific Officer
EpiBiologics

- EPI-326 is a bispecific EGFR EpiTAC that drives targeted degradation of mutant and wild type EGFR specifically within tumours
- Highlighting deep and durable efficacy, favourable safety and PK, and path to IND and clinic for EPI-326
- Demonstrating preclinical advancements with *in vivo* data on additional programs, emphasising catalytic degrader mechanisms and tissue-specific delivery
- Exploring the transformative potential of bispecific antibody degraders for oncology and inflammatory diseases



12.30 Networking Lunch

Enhancing PROTAC Discovery & Optimisation Through Computational Design, PK Prediction & Preclinical Development Strategies

13.30 Applying Computational Modelling & Machine Learning to Streamline Degradation Optimisation & Accelerate PK Prediction



Christin Rakers
Principal Scientist
Computational Chemistry
Merck

- Leveraging predictive modelling and ML-driven tools to accelerate degrader design and optimisation
- Evaluating opportunities and limitations of 3D structural modelling to understand ternary complex formation and degradation mechanisms
- Integrating *in silico* strategies to enhance PK prediction, inform rational design decisions, and streamline development of degraders with improved pharmacokinetic profiles

14.00 Unlocking Undruggable Chromatin Regulators to Advance First-in-Class PROTACs Through Preclinical Discovery & Optimisation



Jamie Im
Director, Medicinal Chemistry
Foghorn Therapeutics

- Identifying ligands for a chromatin regulatory protein with limited prior tractability and validating functional degrader activity
- Optimising degrader architecture through iterative design to enhance potency, selectivity and degradation efficiency
- Outlining challenges and solutions in progressing an advanced preclinical degrader toward development candidate nomination



14.30 Afternoon Networking Break

Expanding Induced Proximity Modalities to Redirect, Inhibit & Stabilise Protein Function for Broader Therapeutic Impact

15.00 Harnessing Molecular Glue-Mediated Stabilisation to Restore Proteostasis & Expand Induced Proximity Beyond Degradation



Christian Ottmann
Founder & Chief Technology Officer
Ambagon Therapeutics

Non-Degrader

- Exploring induced proximity mechanisms that stabilise protein-protein interactions to restore proteostasis in neurodegeneration and cancer
- Applying structure-guided chemistry and biophysical characterisation to optimise cooperativity and target engagement in molecular glue design
- Discussing how Ambagon's platform expands induced proximity beyond degradation to address disease-agnostic biological pathways

Conference Day Two

Thursday, 12th March, 2026



Radosław Nowak
Professor of Immune
Engineering & Drug
Discovery
**The University of
Bonn**

Non-Degrader

15.30 Activating Mutant p53 via Chemically Induced Proximity to Restore Tumour Suppressor Function in Cancer

- Showcasing TRAP-1, a novel small molecule that facilitates ternary complex formation between mutant p53 and BRD4, enabling transcriptional reactivation of p53 in oncogenic contexts.
- Demonstrating robust induction of p53 target genes and selective growth inhibition in p53Y220C pancreatic cancer models, underscoring the mechanistic requirement for chemically induced proximity.
- Establishing TCIPs as a promising therapeutic modality to restore tumour suppressor function and address historically intractable transcription factor targets.

16.00 Chair's Closing Remarks

16.15 End of the 6th TPD & Induced Proximity Summit Europe 2026

TPD & Induced Proximity Europe offers the opportunity for thought leaders to converge and exchange ideas on current best practices, future directions, and all other facets of discovering and developing degraders.

Kevin Wilson, Vice President, Head of Chemistry,
Foghorn Therapeutics





Event Partner

Pharmaron are a leading contract research organisation (CRO) known for our extensive laboratory services and expertise in Target Protein Degradation (TPD).

With advanced facilities and a dedicated team, we specialise in customised solutions for drug discovery and development. Our TPD capabilities allow for precise evaluation of drug stability and efficacy, ensuring the delivery of top-quality pharmaceuticals. With a track record of supporting over 2,000 organisations globally, we have become a trusted and established partner in the biopharmaceutical field.

www.pharmaron.com

“The TPD Summits are renowned meetings in the TPD field which allows for optimal exchange of the latest insights and developments in the (bio) TPD field, also beyond PROTACs and Molecular Glues. Besides, the meeting offers excellent networking opportunities that is essential for a young biotech like ours.”

Maureen Galmes-Spit, Vice President, Research,
Laigo bio

Get Involved



Tom Walsh
Partnerships Director
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

Looking to Form Stronger Bonds in the TPD Community?

6th Annual
TPD & Induced Proximity Summit
Europe
10-12th March 2026 | London, UK

Your Platform to Connect With Induced Proximity Pioneers & Position Your Services at the Heart of TPD Innovation in Europe

The **6th TPD & Induced Proximity Summit Europe** is your unique opportunity to connect with the scientists, decision-makers, and innovators driving the next wave of proximity-based therapeutics. With the European market pivoting toward novel mechanisms and non-oncology indications, drug developers are actively seeking partners who can support them with:



Hit Identification & Screening

through DEL libraries, fragment-based approaches, and phenotypic assays



Medicinal Chemistry & Synthesis

to optimise PROTACs, glues, and emerging modalities



Preclinical CRO Services

for PK/PD modelling, toxicity profiling, and degradation efficiency validation



AI & Computational Platforms

to streamline rational design and predict ternary complex formation

Whether you're a discovery platform, chemistry provider, or CRO, this summit offers direct access to European biotech and pharma teams looking to outsource key stages of their TPD programs. Elevate your brand, showcase your capabilities, and build lasting partnerships with those shaping the future of induced proximity.

Top Reasons to Partner:

Position Your Brand at the Forefront of Proximity Drug Development

Showcase your expertise to a targeted audience of European biotechs and pharma teams actively developing PROTACs, glues, and emerging induced proximity modalities, who are seeking external support for discovery, chemistry, and preclinical validation.


Engage Directly With Decision-Makers Driving Outsourcing Strategies

Meet CXOs, Directors, and Scientists from leading European and US companies during 7+ hours of networking, including poster sessions and speed networking. Understand their challenges and tailor your solutions to their evolving needs.

Maximise Visibility in a Focused, Single-Track Summit

Benefit from speaking opportunities and branding across a streamlined agenda that ensures your message reaches the full audience. With a curated program and high engagement, your presence will leave a lasting impression.

Seniority of Attendees




43% CXO, Founder & President

21% Director & Head

25% Scientist & Researcher

11% Manager

Type of Companies Attending



Statistics taken from the 5th TPD & Induced Proximity Summit Europe

Get Involved



Tom Walsh
Partnerships Director
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

 www.tpd-europe.com/take-part/register/

 Tel: +44 (0)20 3141 8700

 Email: info@hansonwade.com



Accelerate Your Proximity Pipeline With Clinical Insights From Global Leaders

Hear first-hand data from US and EU companies including **Autotac Bio**, **Foghorn Therapeutics**, and **Merck** to inform your strategy and fast-track your candidates



Discover Novel Mechanisms and Modalities Beyond Degradation

Explore how antibody-based molecular glues and stabilisers are expanding the therapeutic potential of induced proximity - especially in CNS and agriculture



Connect With Europe's Most Innovative Biopharma Teams

Network with 80+ senior scientists and decision-makers across three days to build collaborations that drive your TPD programs forward

Drug Developers*	Register By Friday 28 th November to Save Up to £1,000	On the Door
Conference + Pre-Conference Workshop Day	£2,797 (SAVE £1,000)	£3,797
Conference Only	£2,199 (SAVE £500)	£2,699
Academic & Research Institutes**	Register By Friday 28 th November to Save Up to £1,000	On the Door
Conference + Pre-Conference Workshop Day	£2,197 (SAVE £1,000)	£3,197
Conference Only	£1,799 (SAVE £500)	£2,299
Solution & Service Providers	Register By Friday 28 th November to Save Up to £1,000	On the Door
Conference + Pre-Conference Workshop Day	£3,497 (SAVE £1,000)	£4,497
Conference Only	£2,699 (SAVE £500)	£3,199

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organisation? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Millennium Hotel and Conference Centre Gloucester London

4-18 Harrington Gardens, London SW7 4LH

<https://www.millenniumhotels.com/>

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

